Roche and Alnylam report positive detailed results for a Phase II study evaluating a single subcutaneous dose of zilebesiran added to one of three standard antihypertensive agents, in patients with inadequately controlled hypertension.

The KARDIA-2 study met its primary endpoint, demonstrating additive placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHg at month 3, with statistically and clinically significant results.

Zilebesiran also demonstrated an encouraging safety and tolerability profile when added to standard antihypertensive agents. These data were presented at the annual scientific session of the American College of Cardiology (ACC).

Roche and Alnylam have now launched the phase II KARDIA-3 study to evaluate the efficacy of zilebesiran when added to two or more anti-hypertensive drugs in people with uncontrolled hypertension at high cardiovascular risk.

Copyright (c) 2024 All rights reserved.